NCT01474798View on ClinicalTrials.gov

Phase II Trial of RA-18C3 in Subjects With Moderate to Severe Acne Vulgaris

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

October 31, 2012

Study Completion Date

December 31, 2012

Conditions
Acne Vulgaris
Interventions
DRUG

RA-18C3

"For subjects weighing 27-53 kg: 100 mg (1 ml) administered every three weeks by subcutaneous injection.~For subjects weighing \> 53 kg: 200 mg (2 ml) administered every three weeks by subcutaneous injection."

Trial Locations (3)

33709

Meridien Research, St. Petersburg

78705

Austin Dermatology Associates, Austin

90210

Moy, Fincher, and Chipps Facial Plastics and Dermatology, Beverly Hills

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT01474798 - Phase II Trial of RA-18C3 in Subjects With Moderate to Severe Acne Vulgaris | Biotech Hunter | Biotech Hunter